Logotype for Waystar Holding Corp

Waystar (WAY) Q1 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Waystar Holding Corp

Q1 2026 earnings summary

30 Apr, 2026

Executive summary

  • Q1 2026 revenue reached $313.9 million, up 22% year-over-year, with net income of $43.3 million and adjusted EBITDA of $135.4 million, driven by strong subscription growth, AI innovation, and successful integration of Iodine.

  • Over 99% of revenue is recurring, with net revenue retention at 111% and client count with over $100,000 in trailing twelve-month revenue rising to 1,433, up 15% year-over-year.

  • AI-powered solutions now account for 40% of new bookings and nearly 40% of revenue, accelerating platform adoption and expanding the addressable market.

  • Integration of Iodine is ahead of plan, enhancing clinical and financial data convergence, cross-sell opportunities, and AI capabilities.

  • Launched new AI-powered recoupment solution and Prebill Anomaly Detection, delivering strong early ROI for providers.

Financial highlights

  • Q1 2026 revenue was $313.9 million, up 22% year-over-year; subscription revenue grew 38% to $172.2 million (55% of total), and volume-based revenue increased 7% to $139.5 million.

  • Adjusted EBITDA was $135.4 million, up 26% year-over-year, with a 43% margin, slightly above expectations due to favorable revenue mix.

  • Net income for Q1 2026 was $43.3 million, up 47.9% year-over-year, with a net income margin of 14%.

  • Unlevered free cash flow was $90.3 million, converting 67% of adjusted EBITDA.

  • Ended Q1 with $159 million in cash equivalents and $1.5 billion in gross debt; net debt stood at $1.32 billion.

Outlook and guidance

  • FY 2026 revenue guidance is $1.274–$1.294 billion (midpoint $1.284 billion, 17% year-over-year growth), with adjusted EBITDA of $530–$540 million and a margin expected to remain at 42–43%.

  • Non-GAAP net income projected at $317–$335 million and diluted non-GAAP EPS expected between $1.59 and $1.68.

  • Full-year guidance assumes normalized organic revenue growth of ~10% and less seasonality in patient payments.

  • Q2 sequential growth expected to be flat to 1%, with Q3 at 1–3%.

  • Sufficient liquidity is anticipated for at least the next 12 months, with ongoing investments in growth and technology.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more